Navigation Links
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Date:5/28/2009

MELBOURNE, Australia, May 28 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) announced that it will present preliminary data from its Phase I clinical trial of orally administered CYT997, at the Annual Meeting of the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.

Dr Alessandra Francesconi, one of the clinical investigators for the program, will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8:00 AM to 12:00 PM (US EST), Level 2, West Hall C.

The poster entitled "Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer" details safety, tolerability and preliminary activity findings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma.

Enquiries


    Dr. Gregg Smith                            Mr. Andrew Macdonald
    Director, Drug Development and Operations  Chief Executive Officer
    T: +61 3 9208 4234                         T: +61 3 9208 4232
    gregg.smith@cytopia.com.au                 andrew.macdonald@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in mid 2009.

Website: www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Presentation on VDA CYT997 at AACR Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , the commercial and ... McGill University . The partnership is designed to advance research in pain genetics ... patients in pain. With the new agreement, researchers at Proove Biosciences are able to ...
(Date:5/4/2016)... According to a new market ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... expand at a CAGR of 17.1% from 2016 to ... Metabolomics is the extensive study of small molecules, ... organisms. Together, these small molecules and their interactions in ...
(Date:5/3/2016)... PUNE, India , May 3, 2016 ... Type (DNA Chip (Genomics, Drug Discovery, Gene ... Chips), End user (Academics Institutes, Diagnostics Centers), ... 2020" published by MarketsandMarkets, the market is ... 2020 from USD 7.63 Billion in 2015, ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
Breaking Biology Technology:
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
(Date:3/14/2016)... 14, 2016 NXTD ) ("NXT-ID" or ... market, announces the airing of a new series of commercials ... of March 21 st .  The commercials will air on ... Squawk on the Street show. --> NXTD ) ... mobile commerce market, announces the airing of a new series ...
(Date:3/10/2016)... BLUE BELL, Pa. , March 10, 2016   ... U.S. Customs and Border Protection (CBP) is testing ... in San Diego to help identify ... United States . The test, designed to help determine ... outdoor, pedestrian environment, began in February and will run until ...
Breaking Biology News(10 mins):